Clinical Trials Browser

Hodgkin Disease × ibrutinib × Other hematologic neoplasm × Clear all

NCT02869633 2023-10-23

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Phase 2 Completed

23 enrolled 10 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell